556 related articles for article (PubMed ID: 19369454)
41. Practice variation in the treatment of rheumatoid arthritis among German rheumatologists.
Zink A; Listing J; Ziemer S; Zeidler H;
J Rheumatol; 2001 Oct; 28(10):2201-8. PubMed ID: 11669156
[TBL] [Abstract][Full Text] [Related]
42. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.
Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M
Curr Med Res Opin; 2008 Aug; 24(8):2229-40. PubMed ID: 18577308
[TBL] [Abstract][Full Text] [Related]
43. Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic.
Hider SL; Tanveer W; Brownfield A; Mattey DL; Packham JC
Rheumatology (Oxford); 2009 Sep; 48(9):1152-4. PubMed ID: 19608723
[TBL] [Abstract][Full Text] [Related]
44. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
Jacobsson LT; Turesson C; Gülfe A; Kapetanovic MC; Petersson IF; Saxne T; Geborek P
J Rheumatol; 2005 Jul; 32(7):1213-8. PubMed ID: 15996054
[TBL] [Abstract][Full Text] [Related]
45. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry.
Coulson KA; Reed G; Gilliam BE; Kremer JM; Pepmueller PH
J Clin Rheumatol; 2009 Jun; 15(4):155-60. PubMed ID: 19363452
[TBL] [Abstract][Full Text] [Related]
46. The effect of anti-TNF-α vs. DMARDs on fatigue in rheumatoid arthritis patients.
van Hoogmoed D; Fransen J; Repping-Wuts H; Spee L; Bleijenberg G; van Riel PL
Scand J Rheumatol; 2013; 42(1):15-9. PubMed ID: 22992002
[TBL] [Abstract][Full Text] [Related]
47. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders.
La DT; Collins CE; Yang HT; Migone TS; Stohl W
Ann Rheum Dis; 2008 Aug; 67(8):1132-8. PubMed ID: 17967830
[TBL] [Abstract][Full Text] [Related]
48. Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice.
Montag K; Gingold M; Boers A; Littlejohn G
Intern Med J; 2011 Jun; 41(6):450-5. PubMed ID: 20403067
[TBL] [Abstract][Full Text] [Related]
49. Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden.
Söderlin MK; Lindroth Y; Jacobsson LT
Rheumatology (Oxford); 2007 Aug; 46(8):1355-8. PubMed ID: 17567634
[TBL] [Abstract][Full Text] [Related]
50. Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis.
Syngle A; Vohra K; Kaur L; Sharma S
Scand J Rheumatol; 2009; 38(1):15-22. PubMed ID: 18766955
[TBL] [Abstract][Full Text] [Related]
51. Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden.
Gülfe A; Kristensen LE; Saxne T; Jacobsson LT; Petersson IF; Geborek P
Ann Rheum Dis; 2010 Feb; 69(2):352-7. PubMed ID: 19282310
[TBL] [Abstract][Full Text] [Related]
52. Mononuclear cell response to lipopolysaccharide in patients with rheumatoid arthritis: relationship with tristetraprolin expression.
Fabris M; Tolusso B; Di Poi E; Tomietto P; Sacco S; Gremese E; Ferraccioli G
J Rheumatol; 2005 Jun; 32(6):998-1005. PubMed ID: 15940758
[TBL] [Abstract][Full Text] [Related]
53. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.
Haraoui B
J Rheumatol Suppl; 2005 Jan; 72():46-7. PubMed ID: 15660467
[TBL] [Abstract][Full Text] [Related]
54. Biologic therapy for early rheumatoid arthritis: the latest evidence.
Castro-Rueda H; Kavanaugh A
Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
[TBL] [Abstract][Full Text] [Related]
55. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
Keystone E; Freundlich B; Schiff M; Li J; Hooper M
J Rheumatol; 2009 Mar; 36(3):522-31. PubMed ID: 19228659
[TBL] [Abstract][Full Text] [Related]
56. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis.
Tsujimura S; Saito K; Nawata M; Nakayamada S; Tanaka Y
Ann Rheum Dis; 2008 Mar; 67(3):380-8. PubMed ID: 17660216
[TBL] [Abstract][Full Text] [Related]
57. Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study.
Iannaccone CK; Lee YC; Cui J; Frits ML; Glass RJ; Plenge RM; Solomon DH; Weinblatt ME; Shadick NA
Rheumatology (Oxford); 2011 Jan; 50(1):40-6. PubMed ID: 20847201
[TBL] [Abstract][Full Text] [Related]
58. Smoldering rheumatoid arthritis: is the Canadian healthcare system neglecting a significant disease population?
Edworthy S; Zummer M; Garner S; Boire G; Leclercq S; Bykerk V; Kraag G; Markland J; Thomas D; Thomson J; Henderson J
J Rheumatol; 2008 Aug; 35(8):1506-12. PubMed ID: 18597407
[TBL] [Abstract][Full Text] [Related]
59. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
Popa C; van Tits LJ; Barrera P; Lemmers HL; van den Hoogen FH; van Riel PL; Radstake TR; Netea MG; Roest M; Stalenhoef AF
Ann Rheum Dis; 2009 Jun; 68(6):868-72. PubMed ID: 18635596
[TBL] [Abstract][Full Text] [Related]
60. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis.
Tanaka Y
Curr Opin Rheumatol; 2012 May; 24(3):319-26. PubMed ID: 22388646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
